120 related articles for article (PubMed ID: 36152991)
21. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
22. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
23. Monocyte urokinase expression: modulation by interleukins.
Gyetko MR; Wilkinson CC; Sitrin RG
J Leukoc Biol; 1993 May; 53(5):598-601. PubMed ID: 8501398
[TBL] [Abstract][Full Text] [Related]
24. Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine stimulation of endometrial angiogenesis.
Sandberg T; Casslén B; Gustavsson B; Benraad TJ
Biol Reprod; 1998 Oct; 59(4):759-67. PubMed ID: 9746723
[TBL] [Abstract][Full Text] [Related]
25. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
26. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
27. PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
Fabre-Guillevin E; Malo M; Cartier-Michaud A; Peinado H; Moreno-Bueno G; Vallée B; Lawrence DA; Palacios J; Cano A; Barlovatz-Meimon G; Charrière-Bertrand C
Breast Cancer Res; 2008; 10(6):R100. PubMed ID: 19055748
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
29. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
30. The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro.
Chou CS; Zhu H; Shalev E; MacCalman CD; Leung PC
J Clin Endocrinol Metab; 2002 Dec; 87(12):5594-603. PubMed ID: 12466358
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
[TBL] [Abstract][Full Text] [Related]
32. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
33. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Benassi MS; Ponticelli F; Azzoni E; Gamberi G; Pazzaglia L; Chiechi A; Conti A; Spessotto P; Scapolan M; Pignotti E; Bacchini P; Picci P
Histol Histopathol; 2007 Sep; 22(9):1017-24. PubMed ID: 17523079
[TBL] [Abstract][Full Text] [Related]
34. Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Leloup G; Lemoine P; Carmeliet P; Vaes G
J Bone Miner Res; 1996 Aug; 11(8):1146-57. PubMed ID: 8854251
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal fluid reduces angiogenesis-related microRNA expression in cell cultures of endometrial and endometriotic tissues from women with endometriosis.
Braza-Boïls A; Gilabert-Estellés J; Ramón LA; Gilabert J; Marí-Alexandre J; Chirivella M; España F; Estellés A
PLoS One; 2013; 8(4):e62370. PubMed ID: 23620826
[TBL] [Abstract][Full Text] [Related]
37. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
38. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Shin S; Kim MK; Jung W; Chong Y
Phytother Res; 2018 Oct; 32(10):2086-2096. PubMed ID: 30009577
[TBL] [Abstract][Full Text] [Related]
39. Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes.
Zhang T; Zhou HM; Liu YX
Mol Hum Reprod; 1997 Mar; 3(3):223-31. PubMed ID: 9237248
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
